Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program

About this update from Quantum Biopharma Ltd. Subordinate Voting Shares Class B

[{"type":"text","content":"Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program\n\n\n\n TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“\n \n Quantum BioPharma\n \n ” or the “\n \n Company\n \n ”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced it has retained the services of MZHCI, LLC, an MZ Group Company (“\n \n MZ\n \n ”), to lead a comprehensive strategic investor relations and financial communications program across all key markets.\n \n\n MZ will work closely with Quantum BioPharma management to develop and implement a comprehensive capital markets strategy designed to increase the Company’s visibility throughout the investment community. The campaign will highlight how Quantum BioPharma is developing a robust pipeline of products and assets focused on addressing significant unmet needs in brain disorders and alcohol health.\n \n\n Chris Tyson, Executive Vice President at MZ North America, commented, \"unbuzzd™ and rekvry™ utilize revolutionary technology that address the issue of excessive alcohol use. The National Institute of Health found that binge drinking rates among adults aged 35–50 reached an all-time high in 2023, and the CDC reports that excessive drinking costs the U.S. about $249 billion annually when combining healthcare costs, lost productivity and earnings, criminal justice implications, vehicle crashes, and property damages.\n \n\n “Quantum BioPharma is also focused on a potential first-in-class approach to treating demyelinating diseases. Multiple sclerosis (“MS”) is characterized by demyelination, one of a group of disorders characterized by the destruction of myelin, the protective sheath that surrounds nerve fibers in the central nervous system. Almost 1 million people in the U.S. alone have been diagnosed with MS and 2.8 million people worldwide, according to the National Multiple Sclerosis Society.\n \n\n “Led by a world-class research and development team and seasoned commercial experts, these life-changing and exciting opportunities in brain disorders and alcohol health represent a tremendous revenue potential, and we look...

More updates from Quantum Biopharma Ltd. Subordinate Voting Shares Class B